DescriptionProduct Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).Transfection Reagent for 3LL Cells (Lewis Lung Carcinoma Cells)A nanoparticle-based liposome formulationTransfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNATransfection Enhancer reagent provided with the kitProduce higher level of recombinant protein expression with minimal disruption of normal cell functionGenerate physiologically relevant data you can trustEffective for plasmid DNA/siRNA co-transfectionLow cytotoxicityDownload in vitro 3LL transfection protocol: [PDF]Download 3LL CRISPR/Cas9 transfection protocol: [PDF]Download PowerPoint presentation for 3LL cells transfection kit: [PPT]Developed and manufactured by Altogen BiosystemsTransfection Efficiency: Reagent exhibits at least 73% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.Transfection Protocol and MSDS: Download Altogen Biosystems 3LL Transfection Protocol: [PDF] Download MSDS: [PDF]3LL Cell Line: Lung cancer is considered the most preventable malignancy globally. However, it is the deadliest form of cancer with very high mortality rates because of lack of adequate therapies and aggressive tumor cell growth. Rodent cell line models play an essential role in preclinical research to study novel therapeutic agents and treating human cancer. The LLC cell line is a well-studied mouse cancer model that is extensively employed as a transplantable malignancy model. Lewis Lung Carcinoma cells (also known as 3LL cells or LLC cells) got their name after Dr. Margaret R. Lewis of the Wistar Institute, who discovered carcinoma in 1951. This cell line has been known to show reduced metastatic ability when exposed to ultraviolet light. It has also been observed that the presence of cannabinoids suppresses cell growth. These cells could be useful for medical research for treatments to certain types of lung cancer, and many other molecular or cell biology studies. According to the recent data, the proliferative advantage of 3LL metastatic cells is achieved by the gene expression which prevents tumor cells from escaping hostile microenvironmental conditions. Altogen Biosystems provides nanoparticle-based transfection kits for this cell line.Data:Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, 3LL cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).Figure 2. Protein expression of GAPDH in 3LL cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into 3LL cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]Request a Quote for 3LL Transfection ReagentAltogen Biosystems: Altogen Biosystems manufacturers cell type specific and preoptimized transfection products, elecroporation kits, and in vivo delivery reagents for life science research. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.Altogen Research Services: Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com). Volume Options:0.5 ml (Catalog #1701)1.5 ml (Catalog #1702)1.5 ml CRISPR (Catalog #2206)8.0 ml (Catalog #7015)
Altogen Biosystems全国代理部分产品列表：
|
货号
|
产品
|
规格
|
价格（美元）
|
|
5030
|
|
|
|
|
1703
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
0.5ml
|
170
|
|
1704
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml
|
348
窗体顶端
窗体底端
|
|
2101
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml CRISPR
|
548
窗体顶端
窗体底端
|
|
7018
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
8.0ml
|
1044
窗体顶端
窗体底端
|
|
1167
|
A375 Cells Transfection Reagent (CRL-1619)
|
0.5ml
|
195
|
|
1168
|
A375 Cells Transfection Reagent (CRL-1620)
|
1.5ml
|
427
|
|
2102
|
A375 Cells Transfection Reagent (CRL-1621)
|
1.5ml CRISPR
|
627
|
|
1169
|
A375 Cells Transfection Reagent (CRL-1622)
|
8.0ml
|
1281
|
|
5030
|
Nanoparticle In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
445
|
|
5010
|
LIPID In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
405
|
|
5040
|
PEG-Liposome In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
465
|
|
5020
|
POLYMER In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
425
|
|
5050
|
Pancreas In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5060
|
Liver In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5070
|
Kidney In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
1721
|
BMS2 Transfection Reagent (Bone Marrow Cells)
|
0.5 ml
|
231
|
|
6345
|
C6 Transfection Reagent (Glioma Cells, CCL-107)
|
0.5 ml
|
199
|
|
6803
|
DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
|
0.5 ml
|
201
|
|
1775
|
HUH-7 Transfection Reagent (Liver Cancer Cells)
|
0.5 ml
|
179
|
